- Conditions
- Ischemic Heart Failure
- Interventions
- LifeVest
- Device
- Lead sponsor
- Zoll Medical Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Rochester, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Type 1 Diabetes
- Interventions
- Atorvastatin, Placebo
- Drug · Other
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 10 Years to 19 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Atrial Fibrillation New Onset
- Interventions
- Wearable cardiac monitor -Zio patch
- Device
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 70 Years to 100 Years · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Epilepsy, Seizures
- Interventions
- Not listed
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Aralast NP 45 mg dose, Aralast NP 90 mg dose, Aralast NP 180 mg dose
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 8 Years to 35 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 15
- States / cities
- San Diego, California • Aurora, Colorado • New Haven, Connecticut + 10 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- IL-2, Rapamycin
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 3
- States / cities
- New York, New York • Portland, Oregon • Seattle, Washington
- Conditions
- Type 1 Diabetes, New Onset
- Interventions
- Anti-thymocyte globulin (ATG), verapamil extended-release capsule, Adalimumab
- Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 9 Years to 20 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 11
- States / cities
- San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 8 more
- Conditions
- Schizophrenia, Psychotic Disorders, Bipolar Disorder
- Interventions
- Pharmacotherapy, Behavioral treatment
- Drug · Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 26 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Type 1 Diabetes
- Interventions
- Time Limited Eating
- Other
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 12 Years to 25 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Pancreatic Cancer, Pancreatic Neoplasms, Diabetes Mellitus
- Interventions
- MRI/MRCP
- Diagnostic Test
- Lead sponsor
- Nuvance Health
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2028
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • Norwalk, Connecticut
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Anti-CD3 mAb, Diabetes Standard of Care Treatment, Iron supplementation
- Biological · Other · Dietary Supplement
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 8 Years to 30 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 7
- States / cities
- San Francisco, California • Denver, Colorado • New Haven, Connecticut + 3 more
- Conditions
- Anxiety Disorders
- Interventions
- lorazepam, placebo, paroxetine
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 15
- States / cities
- Glendale, California • Northridge, California • Orange, California + 10 more
- Conditions
- Posttransplant Diabetes Mellitus
- Interventions
- Sitagliptin, Placebo
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Colecalciferol 2000 IU, Placebo
- Biological · Dietary Supplement
- Lead sponsor
- Diamyd Medical AB
- Industry
- Eligibility
- 12 Years to 28 Years
- Enrollment
- 321 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 13
- States / cities
- Newport Beach, California • Palo Alto, California • San Diego, California + 10 more
- Conditions
- New-onset Type 1 Diabetes
- Interventions
- Ladarixin, Placebo
- Drug · Other
- Lead sponsor
- Dompé Farmaceutici S.p.A
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Atlanta, Georgia
- Conditions
- Maculopathy, Age-Related, Choroidal Neovascularization
- Interventions
- Not listed
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 4
- States / cities
- Beverly Hills, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- Faster-acting insulin aspart, Insulin aspart, Insulin degludec, Metformin
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 64
- States / cities
- Concord, California • Fresno, California • Fullerton, California + 56 more
- Conditions
- Hypertension
- Interventions
- Nebivolol, Lisinopril
- Drug
- Lead sponsor
- University of Mississippi Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Jackson, Mississippi
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Anti-Thymocyte Globulin (ATG), Granulocyte colony stimulating factor (GCSF), Placebo (for ATG), Placebo (for GCSF)
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 12 Years to 45 Years
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 13
- States / cities
- San Francisco, California • Stanford, California • Aurora, Colorado + 10 more
- Conditions
- Delayed Onset Muscle Soreness
- Interventions
- Loxoprofen Pain Patch, Placebo Patch, No Treatment
- Drug
- Lead sponsor
- Lead Chemical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Colchicine, Inflammation in Cardiac Surgery, Post Operative Atrial Fibrillation, Inflammatory Markers, Colchicine Adverse Reaction
- Interventions
- Colchicine (Colcrys®), Placebo
- Drug
- Lead sponsor
- Ayesha Ather
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Type 1 Diabetes
- Interventions
- Exenatide, Rapid and long acting insulin, long acting insulin + rapid acting + 1.25 mcg Exenatide
- Drug
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2017
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Baricitinib, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 1 Year to 35 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Tallahassee, Florida • Philadelphia, Pennsylvania + 2 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Mycophenolate mofeteil (MMF), Daclizumab (DZB), Placebo control for Mycophenolate mofeteil (MMF), Placebo control for Daclizumab (DZB)
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 8 Years to 45 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 10
- States / cities
- Los Angeles, California • San Francisco, California • Stanford, California + 7 more